In recent years, Russia has charted a clear course for domestic pharmaceutical production, targeting an almost doubling of in-country production with the aim of reaching 50% by 2020. At the same time, there are plans to bring the legal framework for the drug market in line with international standards. How is this policy being implemented, and how might it impact both foreign and domestic producers over the coming years? What main problems are being encountered by the sector and what should be done to overcome these issues? What steps need to be taken to ensure that Russian patients have uninterrupted access to quality medicines?